Vector BioMed launches with $15M to produce backlogged CAR-T component

The manufacture of lentiviral vectors has been grabbing the attention of investors both small and large as of late, and another manufacturer is looking to jump onto the scene. Vector BioMed, a Maryland-based biomanufacturing company, has raised $15 million, according to CEO Boro Dropulić in an interview with Endpoints News.…

Click here to view original post